<DOC>
	<DOCNO>NCT00636545</DOCNO>
	<brief_summary>The primary objective determine safety maximum tolerate dose ( MTD ) Genasense administer 2-hour intravenous infusion weekly ( Part 1 ) twice weekly ( Part 2 ) patient solid tumor .</brief_summary>
	<brief_title>Genasense 2-hour Intravenous Infusion Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis solid tumor malignancy , include lymphoma , fail standard therapy standard therapy available Adequate organ function determine â‰¤ 7 day prior start study medication Eastern Cooperative Oncology Group performance status 0 2 At least 3 week recovery effect major prior surgery therapy , include chemotherapy , radiation therapy , immunotherapy , cytokine , biologic , vaccine therapy Exclusion criteria Other significant medical disease History presence leptomeningeal disease Coexisting condition would require subject continue therapy treatment phase study drug know alter renal function Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Genasense</keyword>
	<keyword>oblimersen</keyword>
	<keyword>antisense</keyword>
	<keyword>Bcl-2 antisense</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>